Halozyme Therapeutics has made an unsolicited bid to acquire Evotec for 11 euros per share, with an estimated total value of around 2 billion euros. This move is aimed at enhancing the scale of operations and creating a stronger partner in the drug industry.
Evotec has responded by stating that it will carefully analyze the bid.
Bluebird Bio has achieved a significant milestone by recording its first revenue from the sale of Lyfgenia, a gene therapy for sickle cell disease. The therapy is priced at $3.1 million and has seen growing demand.
BeiGene has rebranded as BeOne Medicines to reflect its commitment to oncology research and distance itself from its origins in China.
Adaptimmune plans to lay off a third of its workforce as part of a strategy to save $300 million and achieve financial sustainability.
Abeona Therapeutics is awaiting a critical decision from the FDA regarding its gene therapy, pz-cel, for recessive dystrophic epidermolysis bullosa. The FDA has set a target decision date of April 29, 2025.